Door-to-Needle Time and the Proportion of Patients Receiving Intravenous Thrombolysis in Acute Ischemic Stroke: Uniform Interpretation and Reporting

Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA) is one of very few effective treatments for acute ischemic stroke. Still, in most centers, only a small proportion (2%–7%) of patients with ischemic stroke receive this treatment in daily practice.1–3 The most important factor limiting IVT administration is time because it has to be administered within 4.5 hours of symptom onset. Even within this time window, the clinical benefit from IVT declines rapidly (time is brain), and every minute counts.4 If IVT is started within 90 minutes after stroke onset, the number of patients needed to treat to achieve an excellent clinical outcome modified Rankin scale score (0–1) is 4. Within the 180–270-minute time window, this number dramatically increases to 14.5 In other words, a shorter delay from symptom to IVT, the so-called symptom-to-needle time, can make the difference between being independent and being dependent. Reducing the symptom-to-needle time requires several hurdles to be jumped. Most time is lost in the prehospital period, the so-called symptom-to-door time to symptom-to-needle time, mainly because of patients waiting before they seek medical attention. However, this is difficult to accomplish because campaigns aimed at raising public awareness of stroke symptoms have only limited impact on behavior.6 Inside the hospital, focus should be on decreasing the time from arrival to IVT administration, the so-called door-to-needle time (DNT). Besides improved functional outcome, a reduced DNT will also increase the proportion of patients eligible for IVT because more patients can be treated before the 4.5-hour time limit.7 Unfortunately, >15 years after IVT was proven to be clinically effective, in most institutions, the DNT is still >60 minutes for the majority of patients.7,8 In most countries, national guidelines recommend that the DNT should not exceed this 60-minute limit. …

[1]  H. Gold,et al.  Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis. , 1986, The American journal of cardiology.

[2]  M. Kaste,et al.  The European Cooperative Acute Stroke Study (ECASS) , 1993 .

[3]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[4]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[5]  M. Moerland,et al.  Endothelial Binding of Recombinant Tissue Plasminogen Activator: Quantification In Vivo Using a Recirculatory Model , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[6]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[7]  M. Hammer,et al.  Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. , 2004, Archives of neurology.

[8]  V. Larrue.  Intravenous alteplase for acute ischaemic stroke , 2005, Expert opinion on pharmacotherapy.

[9]  Werner Hacke,et al.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.

[10]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[11]  I. Bone,et al.  Implementation of a stroke thrombolysis service within a tertiary neurosciences centre in the United Kingdom. , 2008, QJM : monthly journal of the Association of Physicians.

[12]  J. V. van Wijngaarden,et al.  Hospital Rates of Thrombolysis for Acute Ischemic Stroke: The Influence of Organizational Culture , 2009, Stroke.

[13]  S. Y. Kim,et al.  Pre‐hospital notification reduced the door‐to‐needle time for iv t‐PA in acute ischaemic stroke , 2009, European journal of neurology.

[14]  Lorenz Breuer,et al.  Weight Approximation in Stroke Before Thrombolysis: The WAIST-Study: A Prospective Observational “Dose-Finding” Study , 2010, Stroke.

[15]  Gyeong-Moon Kim,et al.  A Computerized In-Hospital Alert System for Thrombolysis in Acute Stroke , 2010, Stroke.

[16]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.

[17]  Mark Parsons,et al.  Implementation and outcome of thrombolysis with alteplase 3–4·5 h after an acute stroke: an updated analysis from SITS-ISTR , 2010, The Lancet Neurology.

[18]  Robbert Huijsman,et al.  Promoting Thrombolysis in Acute Ischemic Stroke , 2011, Stroke.

[19]  B. Gersh.  Association Between Timeliness of Reperfusion Therapy and Clinical Outcomes in ST-Elevation Myocardial Infarction , 2011 .

[20]  J. V. van Wijngaarden,et al.  Do centres with well-developed protocols, training and infrastructure have higher rates of thrombolysis for acute ischaemic stroke? , 2011, QJM : monthly journal of the Association of Physicians.

[21]  G. Donnan,et al.  How to make better use of thrombolytic therapy in acute ischemic stroke , 2011, Nature Reviews Neurology.

[22]  Lorenz Breuer,et al.  Avoiding in Hospital Delays and Eliminating the Three-Hour Effect in Thrombolysis for Stroke , 2011, International journal of stroke : official journal of the International Stroke Society.

[23]  Eric E. Smith,et al.  Improving Door-to-Needle Times in Acute Ischemic Stroke: The Design and Rationale for the American Heart Association/American Stroke Association's Target Stroke Initiative , 2011, Stroke.

[24]  Dawn Kleindorfer,et al.  Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States: A Doubling of Treatment Rates Over the Course of 5 Years , 2011, Stroke.

[25]  E. Ringelstein,et al.  Impact of the Extended Thrombolysis Time Window on the Proportion of Recombinant Tissue-Type Plasminogen Activator-Treated Stroke Patients and on Door-to-Needle Time , 2011, Stroke.

[26]  Adrian F Hernandez,et al.  Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke: Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes , 2011, Circulation.

[27]  Atte Meretoja,et al.  Reducing in-hospital delay to 20 minutes in stroke thrombolysis , 2012, Neurology.

[28]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[29]  D. Leys,et al.  Safety of Thrombolysis in Stroke Mimics: Results From a Multicenter Cohort Study , 2013, Stroke.

[30]  J. Grotta,et al.  Posterior Circulation Stroke is Associated with Prolonged Door-to-Needle Time , 2015, International journal of stroke : official journal of the International Stroke Society.